Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,051,440
  • Shares Outstanding, K 3,100,608
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,049 M
  • EBITDA $ 14,436 M
  • 60-Month Beta 0.47
  • Price/Sales 4.40
  • Price/Cash Flow 12.05
  • Price/Book 4.94

Options Overview Details

View History
  • Implied Volatility 26.64% ( +1.47%)
  • Historical Volatility 27.96%
  • IV Percentile 88%
  • IV Rank 57.22%
  • IV High 34.77% on 10/31/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.63
  • Today's Volume 22,841
  • Volume Avg (30-Day) 17,311
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 184,743
  • Open Int (30-Day) 145,214

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.04
  • Number of Estimates 5
  • High Estimate 1.09
  • Low Estimate 0.99
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +42.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.94 +0.46%
on 11/12/24
78.65 -19.61%
on 10/16/24
-14.62 (-18.78%)
since 10/15/24
3-Month
62.94 +0.46%
on 11/12/24
87.68 -27.88%
on 08/30/24
-21.67 (-25.52%)
since 08/15/24
52-Week
60.47 +4.56%
on 02/12/24
87.68 -27.88%
on 08/30/24
+0.10 (+0.16%)
since 11/15/23

Most Recent Stories

More News
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination

Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...

CMPS : 5.04 (+3.07%)
PSIL : 12.58 (+0.80%)
ATAI : 1.6100 (+17.52%)
AZN : 63.23 (-2.78%)
BVNRY : 8.1300 (-14.24%)
NVAX : 7.32 (+1.39%)
MRNA : 36.85 (-7.34%)
CYBN : 11.60 (+5.45%)
GSK : 33.35 (-1.91%)
PFE : 24.80 (-4.69%)
BNTX : 99.72 (-3.71%)
SNY : 47.97 (+0.31%)
Kennedy’s Nomination Raises Stakes for FDA and Big Pharma

Robert F. Kennedy Jr., recently named President-elect Donald Trump’s nominee for Health and Human Services Secretary, has pledged sweeping reforms at the U.S. Food and Drug Administration (FDA). Kennedy,...

AZN : 63.23 (-2.78%)
MRNA : 36.85 (-7.34%)
PFE : 24.80 (-4.69%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.3600 (-0.92%)
AZN : 63.23 (-2.78%)
JNJ : 154.00 (+1.40%)
MRK : 96.31 (-2.08%)
ABBV : 164.99 (-2.74%)
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?

AstraZeneca just released some encouraging data about its weight loss drug candidates.

AZN : 63.23 (-2.78%)
LLY : 746.20 (-4.93%)
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript

AZN earnings call for the period ending September 30, 2024.

AZN : 63.23 (-2.78%)
AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

AstraZeneca’s AZN third-quarter 2024 core earnings of $1.04 per American depositary share (ADS) beat the Zacks Consensus Estimate of $1.01 per share. Core earnings of $2.08 per share fell 20% year over...

AZN : 63.23 (-2.78%)
AMGN : 283.61 (-4.16%)
SNY : 47.97 (+0.31%)
Building Permits, Vehicle Sales Due Next Week

Monday U.S. Featured Earnings Monday.Com Ltd (NASDAQ: MNDY) (Q3) EPS of four cents, compared ...

BABA : 88.59 (-2.20%)
HAFN : 5.27 (-2.59%)
AMAT : 168.88 (-9.20%)
CSCO : 57.46 (-0.79%)
NVA.TO : 13.15 (+0.92%)
NU : 14.06 (-7.44%)
BN : 56.79 (-1.75%)
COCH : 2.14 (+0.47%)
DIS : 115.08 (+5.46%)
SHOP : 108.49 (-0.54%)
ARMK : 37.36 (-3.41%)
ZETA : 17.58 (+1.21%)
Buy, Sell, or Hold AstraZeneca Stock? Key Tips Ahead of Q3 Earnings

Key TakeawaysZacks earnings estimates for AstraZeneca are currently at $4.06 per share. However, the earnings picture appears to brighten in 2025.The healthcare company has beaten earnings estimates in...

AZN : 63.23 (-2.78%)
NVO : 101.74 (-3.40%)
LLY : 746.20 (-4.93%)
SNY : 47.97 (+0.31%)
Are Options Traders Betting on a Big Move in AstraZeneca (AZN) Stock?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $35.00 Call had some of the highest implied volatility...

AZN : 63.23 (-2.78%)
3 Magnificent Stocks Under $100 to Buy in November

The price could be right for these stocks.

AZN : 63.23 (-2.78%)
SMMT : 18.31 (-5.86%)
MRK : 96.31 (-2.08%)
EXEL : 34.45 (-1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 64.66
2nd Resistance Point 64.35
1st Resistance Point 63.79
Last Price 63.23
1st Support Level 62.92
2nd Support Level 62.61
3rd Support Level 62.05

See More

52-Week High 87.68
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
Last Price 63.23
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar